May 29, 2025 08:14 AM EDT

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

Kyle LaHucik

Biotech Correspondent

Merck and Daiichi Sankyo have pulled the biologics license application for their HER3 antibody-drug conjugate.

The companies said Thursday that they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Summit says bispecific misses overall survival in closely-watched lung cancer study

Large pharma companies spell out reasons why tariffs will harm US investments

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Intellia reports case of liver toxicity in ATTR gene editing study

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation